The Library
Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
Tools
Tools
Tools
Umemneku-Chikere, Chinyereugo M., Ayodele, Olubukola, Soares, Marta, Khan, Sam, Abrams, Keith R., Owen, Rhiannon and Bujkiewicz, Sylwia (2022) Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups. Frontiers in Oncology, 12 . 943154. doi:10.3389/fonc.2022.943154 ISSN 2234-943X. [ 🗎 Public]. [ (✓) hoa:511 ]
|
PDF
WRAP-Comparative-review-of-pharmacological-therapies-in-individuals-with-HER2-positive-advanced-breast-cancer-with-focus-on-hormone-receptor-subgroups-Abrams-2022.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (2715Kb) | Preview |
Official URL: http://dx.doi.org/10.3389/fonc.2022.943154
Abstract
Breast cancer is the fifth leading cause of cancer-related deaths worldwide. The randomized controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2)–positive advanced breast cancer (ABC) have provided an evidence base for regulatory and reimbursement agencies to appraise the use of cancer therapies in clinical practice. However, a subset of these patients harbor additional biomarkers, for example, a positive hormone receptor status that may be more amenable to therapy and improve overall survival (OS). This review seeks to explore the reporting of evidence for treatment effects by the hormone receptor status using the RCT evidence of targeted therapies for HER2-positive ABC patients. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed to identify published RCTs. Extracted data were synthesized using network meta-analysis to obtain the relative effects of HER2-positive-targeted therapies. We identified a gap in the reporting of the effectiveness of therapies by the hormone receptor status as only 15 out of 42 identified RCTs reported hormone receptor subgroup analyses; the majority of which reported progression-free survival but not OS or the overall response rate. In conclusion, we recommend that future trials in ABC should report the effect of cancer therapies in hormone receptor subgroups for all outcomes.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Science > Statistics | ||||||||
| Library of Congress Subject Headings (LCSH): | Breast -- Cancer -- Research, Metastasis -- Research, Breast -- Cancer -- Treatment -- Research, HER-2 gene | ||||||||
| Journal or Publication Title: | Frontiers in Oncology | ||||||||
| Publisher: | Frontiers Research Foundation | ||||||||
| ISSN: | 2234-943X | ||||||||
| Official Date: | 18 August 2022 | ||||||||
| Dates: |
|
||||||||
| Volume: | 12 | ||||||||
| Number of Pages: | 12 | ||||||||
| Article Number: | 943154 | ||||||||
| DOI: | 10.3389/fonc.2022.943154 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||||||
| Date of first compliant deposit: | 18 October 2022 | ||||||||
| Date of first compliant Open Access: | 20 October 2022 | ||||||||
| RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
